David S.P. Tan

10.1k total citations · 2 hit papers
181 papers, 5.1k citations indexed

About

David S.P. Tan is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, David S.P. Tan has authored 181 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Oncology, 67 papers in Reproductive Medicine and 58 papers in Molecular Biology. Recurrent topics in David S.P. Tan's work include Ovarian cancer diagnosis and treatment (67 papers), PARP inhibition in cancer therapy (35 papers) and Endometrial and Cervical Cancer Treatments (21 papers). David S.P. Tan is often cited by papers focused on Ovarian cancer diagnosis and treatment (67 papers), PARP inhibition in cancer therapy (35 papers) and Endometrial and Cervical Cancer Treatments (21 papers). David S.P. Tan collaborates with scholars based in Singapore, United Kingdom and United States. David S.P. Tan's co-authors include Stan B. Kaye, Stanley B. Kaye, Jorge S. Reis‐Filho, Emma Kipps, Roshan Agarwal, Natalie Y.L. Ngoi, Mitch Dowsett, Alan Mackay, Caterina Marchiò and Rachael Natrajan and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Nature reviews. Cancer.

In The Last Decade

David S.P. Tan

159 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research

2013 416 citations David S.P. Tan et al. profile →
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2023 149 citations Antonio González-Martı́n, Alexandra Léary et al. Annals of Oncology profile →

Peers

Countries citing papers authored by David S.P. Tan

Since Specialization

Citations

This map shows the geographic impact of David S.P. Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David S.P. Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David S.P. Tan more than expected).

Fields of papers citing papers by David S.P. Tan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David S.P. Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David S.P. Tan. The network helps show where David S.P. Tan may publish in the future.

Co-authorship network of co-authors of David S.P. Tan

This figure shows the co-authorship network connecting the top 25 collaborators of David S.P. Tan. A scholar is included among the top collaborators of David S.P. Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David S.P. Tan. David S.P. Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Low creatinine to cystatin C ratio is associated with lower muscle volumes and poorer gait speeds in the longitudinal Integrated Women's Health Program cohort 2025 ·Menopause The Journal of The North American Menopause Society ·David S.P. Tan, (unknown), Liang Shen, Ling‐Jun Li, Eu‐Leong Yong	0
2	Pregnancy hypertension is associated with higher p-tau217 in healthy midlife women 2025 ·The Journal of Prevention of Alzheimer s Disease ·Eu‐Leong Yong, (unknown), David S.P. Tan, Liang Shen, (unknown), Joyce R. Chong, Christopher Chen	0
3	Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial 2025 ·Clinical Cancer Research ·Natalie Y.L. Ngoi, Chel Hun Choi, (unknown), Diana Lim, Tuan Zea Tan, Haoyang Sun, Valerie Heong, Samuel G.W. Ow, Wen Yee Chay, (unknown), (unknown), (unknown), Geraldine Goss, Jeffrey C. Goh, Jae‐Weon Kim, Michael Friedländer, Bee Choo Tai, Kidong Kim, David S.P. Tan	2
4	A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients 2025 ·British Journal of Cancer ·(unknown), Tuan Zea Tan, Jae‐Weon Kim, (unknown), (unknown), David Micklem, Akil Jackson, David J. Pinato, Charlie Gourley, Rebecca Kristeleit, Sarah P. Blagden, Line Bjørge, David S.P. Tan	0
5	Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis 2024 ·Gynecologic Oncology ·(unknown), Kyung Hee Han, Eun Young Park, (unknown), (unknown), David S.P. Tan, Jung-Yun Lee, Sang‐Yoon Park, Christina Fotopoulou, (unknown)	8
6	Preliminary efficacy of pembrolizumab plus lenvatinib in recurrent clear cell gynecological cancer: Phase II LARA trial (GCGS-OV4/APGOT-OV3) 2024 ·Byoung‐Gie Kim, Chel Hun Choi, Natalie Y.L. Ngoi, David S.P. Tan, Jae‐Weon Kim	0
7	A three-arm randomized phase II study of dostarlimab alone or with bevacizumab versus nonplatinum chemotherapy in recurrent gynecological clear cell carcinoma: DOVE (APGOT-OV7/ENGOT-ov80 study). 2024 ·Journal of Clinical Oncology ·(unknown), David S.P. Tan, (unknown), Jung Bok Lee, (unknown), Els Van Nieuwenhuysen, Ruby Yun‐Ju Huang, Ka Yu Tse, Antonio González-Martı́n, Clare L. Scott, Kosei Hasegawa, Katie Wilkinson, (unknown), Rebecca Kristeleit	4
8	Personalised Drug Identifier for Cancer Treatment with Transformers using Auxiliary Information 2024 ·(unknown), Hansheng Xue, (unknown), (unknown), (unknown), David S.P. Tan, Tuan Zea Tan, Jason J. Pitt, Anand D. Jeyasekharan, Vaibhav Rajan	0
9	Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience 2024 ·Journal of Gynecologic Oncology ·(unknown), Natalie Y.L. Ngoi, (unknown), Tuan Zea Tan, Diana Lim, (unknown), Yee Liang Thian, (unknown), (unknown), (unknown), Joseph Ng, Jeffrey Low, A. Ilancheran, (unknown), (unknown), David S.P. Tan	5
10	Targeting the immune microenvironment for ovarian cancer therapy 2023 ·Frontiers in Immunology ·Félix Blanc‐Durand, (unknown), David S.P. Tan	33
11	The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women’s cancer research organization 2023 ·Journal of Gynecologic Oncology ·David S.P. Tan, Noriko Fujiwara, Keiichi Fujiwara, Philip Beale, Jae‐Weon Kim, Joseph Ng, Se Ik Kim, (unknown), Byoung‐Gie Kim, (unknown)	0
12	PR024/#394 Molecular profiling of P53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches 2023 ·Félix Blanc‐Durand, (unknown), Etienne Rouleau, Antoine Vasseur, Tjalling Bosse, Stephanie M. de Boer, Richard J. Edmondson, Melanie Powell, Emma J. Crosbie, Naveena Singh, Jessica N. McAlpine, Helen Mackay, Pamela M. Pollock, Linda Mileshkin, Clare L. Scott, (unknown), (unknown), Natalie Y.L. Ngoi, David S.P. Tan, Alexandra Léary	0
13	Closing the gap for cervical cancer research in Vietnam: current perspectives and future opportunities: a report from the 5th Gynecologic Cancer InterGroup (GCIG) Cervical Cancer Research Network (CCRN) Education Symposium 2023 ·Journal of Gynecologic Oncology ·(unknown), (unknown), Nhan P. T. Nguyen, Hang Thu Nguyen, (unknown), (unknown), Katherine Bennett, (unknown), Marie Plante, Dong Hoon Suh, Remi A. Nout, David S.P. Tan	0
14	788P Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches 2023 ·Annals of Oncology ·Félix Blanc‐Durand, Christopher M. Kramer, Etienne Rouleau, Damien Vasseur, Tjalling Bosse, Stephanie M. de Boer, Richard J. Edmondson, Melanie Powell, Emma J. Crosbie, Naveena Singh, Jessica N. McAlpine, Helen Mackay, Pamela M. Pollock, Linda Mileshkin, Clare L. Scott, Natalie Y.L. Ngoi, (unknown), (unknown), David S.P. Tan, Alexandra Léary	0
15	Combined modality management of advanced cervical cancer including novel sensitizers 2022 ·International Journal of Gynecological Cancer ·Michelle Tseng, Natalie Y.L. Ngoi, David S.P. Tan, (unknown)	1
16	Sociodemographic characteristics, depressive symptoms, and increased frequency of intimate partner violence among LGBTQ people in the United States during the COVID-19 pandemic: A brief report 2022 ·Journal of Gay & Lesbian Social Services ·Christopher B. Stults, Kristen D. Krause, Richard J. Martino, Marybec Griffin, Caleb LoSchiavo, (unknown), Stephan A. Brandt, David S.P. Tan, (unknown), (unknown), Jessie J. Wong, Perry N. Halkitis	5
17	Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients withBRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore 2021 ·Journal of Gynecologic Oncology ·David S.P. Tan, Jack Junjie Chan, Robert Hettle, (unknown), (unknown), (unknown)	6
18	Does external beam radiation boost to pelvic lymph nodes improve outcomes in patients with locally advanced cervical cancer? 2019 ·BMC Cancer ·(unknown), Bok Ai Choo, David S.P. Tan, A. Ilancheran, Joseph Ng, Jeffrey Low, Liang Shen, (unknown), (unknown)	19
19	Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study 2017 ·International Journal of Cancer ·Valerie Heong, Nicholas Syn, (unknown), Nur Sabrina Sapari, (unknown), (unknown), (unknown), Diana Lim, Brendan Pang, Yee Liang Thian, (unknown), Andrea Li‐Ann Wong, Ross A. Soo, Wei Peng Yong, Cheng Ean Chee, Soo Chin Lee, Boon Cher Goh, Richie Soong, David S.P. Tan	9
20	Promising SINEs for Embargoing Nuclear–Cytoplasmic Export as an Anticancer Strategy 2014 ·Cancer Discovery ·David S.P. Tan, Philippe L. Bédard, John Kuruvilla, Lillian L. Siu, Albiruni Ryan Abdul Razak	75

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact